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Summary 
 The Fc receptor (FcγRIIb) inhibits B cell responses when coengaged with B cell receptor 
(BCR), and has become a target for new autoimmune disease therapeutics. For example, BCR 
and FcγRIIb coengagement via the Fc-engineered anti-CD19 XmAb5871 suppresses humoral 
immune responses. We now assess effects of XmAb5871 on other activation pathways, including 
the pathogen-associated molecular pattern receptor, TLR9. Since TLR9 signaling is implicated in 
autoimmune diseases, we asked if XmAb5871 could inhibit TLR9 costimulation. We show that 
XmAb5871 decreases ERK and AKT activation, cell proliferation, cytokine and IgG production 
induced by BCR and/or TLR9 signals. XmAb5871 also inhibited differentiation of citrullinated 
peptide-specific plasma cells from rheumatoid arthritis patients. XmAb5871 may therefore have 
potential to suppress pathogenic B cells in autoimmune diseases. 
 3
Introduction 
Coengagement of the B cell receptor (BCR) and the Fcγ receptor IIb (FcγRIIb) by 
immune complexes selectively suppresses activation of B cells recognizing the cognate antigen.1-
3 FcγRIIb is a negative coreceptor for BCR, having an immunoreceptor tyrosine-based inhibitory 
motif (ITIM) on its intracellular tail.4, 5 ITIM is phosphorylated after coligation of FcγRIIb and 
BCR, and recruits SH2 domain-containing inositol 5-phosphatase (SHIP) to inhibit signal 
transduction.6-9 CD19 is a B cell-specific transmembrane glycoprotein that is expressed from the 
pre-B cell until the plasma cell stage.10,11, 12 In contrast to FcγRIIb, CD19 functions as a positive 
coreceptor of BCR, and its intracellular domain contains several immunoreceptor tyrosine-based 
activation motif (ITAM)-like regions that may serve as targets for tyrosine kinases.13,14 After 
being phosphorylated, CD19 recruits Lyn tyrosine kinase, phosphatidyl inositol 3 kinase (PI3-K), 
and the guanine nucleotide exchange factor Vav to the signaling complex, thus lowering the 
threshold for B cell activation.15 However, crosslinking of CD19 may also inhibit B cells, 
depending on the context of activation.16  
To mimic the inhibitory effect of immune complexes, a series of humanized monoclonal 
CD19-specific antibodies have previously been generated with modified Fc domains.17 The 
leading antibody, XmAb5871, binds to human FcγRIIb with >400 higher affinity than native 
IgG1 antibody, and is now in clinical trials as a treatment for rheumatoid arthritis (RA).18,19,20,21 
CD19 and CD32b coengagement by XmAb5871 on the B cell surface results in recruitment of 
SHIP to the phosphorylated ITIM of FcγRIIb.18 SHIP dephosphorylates phosphatidylinositol 
(3,4,5)-triphosphate (PIP3), consequently suppressing activation of pleckstrin homology (PH) 
domain-containing molecules such as AKT.22 Phosphorylated SHIP also binds Dok1, another 
adaptor that inactivates Ras and thus inhibits the Ras-MAPK pathway.23 
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Dysfunction of FcγRIIb is critical in the development of autoimmune diseases such as 
RA.3,24,25 B cells play crucial roles in RA, for example, by producing auto-antibodies against 
citrullinated self proteins. Consequently, the most sensitive and specific marker for RA is the 
presence of anti-citrullinated protein/peptide antibodies (ACPAs) in sera.26,27,28  
By suppressing CD19+ B cell functions via the physiological FcγRIIb inhibitory pathway, 
XmAb5871 has the potential to suppress autoimmunity without chronic B cell depletion. Indeed, 
Horton et. al have shown that XmAb5871 suppressed humoral immunity against tetanus toxoid 
and reduced serum antibody levels in SCID mice engrafted with human peripheral blood 
mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).19 More 
recent studies have demonstrated similar B cell inhibition and suppression of humoral responses 
in patients with RA.20 
We have now expanded these previous studies by investigating if XmAb5871 is able to 
suppress not only BCR, but also TLR9-mediated activation signals, when these stimuli are acting 
independently or synergistically. The innate receptor TLR9 is expressed on intracellular 
endosomal membranes, and recognizes unmethylated DNA from bacteria or released from 
apoptotic cells.29, 30 TLR9 and BCR act synergistically in human B cells, inducing enhanced 
proliferation, cytokine and antibody production; thus, TLR9 plays a crucial role in breaking 
tolerance and developing autoimmunity.31,32 We show here that XmAb5871 inhibits proliferation 
and cytokine secretion of B cells induced by TLR9 and by synergistic stimulation via both BCR 
and TLR9. Additionally, XmAb5871 reduced citrullinated peptide-specific IgG production by B 
cells of RA patients, suggesting that it has potential to suppress autoantibody production in this 
and other immune-mediated diseases. 
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Results  
XmAb5871 downregulates AKT, and ERK phosphorylation in an FcγRIIb-dependent 
manner. 
XmAb5871 has been previously shown to mediate phosphorylation of FcγRIIb and SHIP in 
human B cells.18, 19 To investigate the inhibitory potential of XmAb5871 on the AKT and 
Ras/MAPK pathways activated by anti-Ig and CpG ODN, we first assessed FcγRIIb Y292 
phosphorylation, which contributes to the transduction of FcγRIIb-mediated inhibitory signals. 
Purified tonsillar resting B cells pretreated with XmAb5871 showed a strong FcγRIIb 
phosphorylation at tyrosine 292 as detected by specific antibody (Fig. 1). Treatment with the 
CD19-specific control mAb, XENP6187, that has mutations in the Fc domain (G236R and 
L328R) and thus is unable to bind to Fcγ receptors (anti-CD19-FcKO),18 anti-Ig and CpG ODN 
stimulation (alone or in combination) did not induce FcγRIIb phosphorylation, indicating that 
high-affinity coengagement of FcγRIIb and CD19 by XmAb5871 is necessary and sufficient to 
stimulate FcγRIIb inhibitory signaling.  
To elucidate the inhibitory potential of phosphorylated FcγRIIb on BCR and TLR9 induced 
activation of the AKT and Ras/MAPK pathways, paralell samples were tested for 
phosphorylation of AKT and ERK kinases. Anti-Ig, but not CpG, induced strong AKT 
phosphorylation, which was approximately similar after dual anti-Ig and CpG stimuli. The Fc-
KO antibody XENP6187 slightly enhanced AKT phosphorylation in all samples including the 
nonstimulated control and the CpG ODN-induced ones, presumably due to CD19 crosslinking,33 
while in marked contrast, XmAb5871 blocked both CD19 and BCR-induced AKT 
phosphorylation. Anti-Ig was more effective than CpG for ERK activation. CpG ODN somewhat 
enhanced anti-Ig-stimulated ERK phosphorylation, and XENP6187 slightly enhanced phospho-
 6
ERK signal in the CpG stimulated sample, while XmAb5871 inhibited ERK phosphorylation in 
all samples, even dual-stimulated ones, compared to the XENP6187-treated cells (Fig.1). These 
data indicate that coligation of FcγRIIb and CD19 upon stimulation via BCR and TLR9 induces 
phospho-ITIM-dependent downregulation of AKT and ERK activation in B cells. 
 
Intracellular calcium mobilization induced by BCR and CD19 coengagement is inhibited 
by the enhanced binding of XmAb5871 to FcγRIIb. 
Crosslinking of BCR with CD19 on B cells increases intracellular calcium ion concentration [Ca 
2+]i.9 We compared the effect of XmAb5871 and the Fc-KO control XENP6187 on the BCR-
induced calcium response. CD19 engagement alone in samples treated with XENP6187 or 
XmAb5871 did not induce Ca 2+ mobilization in B cells. As compared to untreated cells, 
XENP6187 pretreatment enhanced [Ca 2+] i in response to anti-Ig stimulation that crosslinks BCR 
and CD19, while XmAb5871 diminished calcium mobilization, indicating that its high affinity 
binding to FcγRIIb overcomes the CD19-induced enhancing effect (Fig. 2).     
 
XmAb5871 inhibits B cell proliferation triggered by anti-Ig and CpG ODN. 
To test if the FcγRIIb-enhanced anti-CD19 antibody can interfere with cell proliferation, purified 
B cells were treated with XmAb5871 or XENP6187 and stimulated via BCR, TLR9, or both 
receptors. A CFSE dilution assay was used for assessing cellular proliferation (Fig. 3a). In 
agreement with previous results,32, 34 anti-Ig synergistically enhanced CpG-induced cell 
proliferation, which was significantly inhibited by both the Fc-KO control antibody XENP6187 
and by XmAb5871 (Fig. 3b). However, the number of dividing cells in XmAb5871-treated and 
anti-Ig plus CpG-stimulated samples was approximately half that of the XENP6187-treated ones. 
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XmAb5871 treatment significantly (p<0.05) reduced proliferation of both CpG- and anti-Ig plus 
CpG-stimulated samples as compared to the untreated control cells.  
 
XmAb5871 blocks cytokine secretion induced by synergistic BCR and TLR9-mediated 
signals. 
B cells stimulated via BCR and TLR9 can secrete both pro-inflammatory and anti-inflammatory 
cytokines, and such dual stimulation has a synergistic effect on interleukin (IL)-6, tumor necrosis 
factor (TNF) and IL-10 secretion (unpublished results). We therefore compared the effect of the 
control XENP6187 and FcγRIIb-enhanced anti-CD19 antibodies on B cell secretion of IL6, TNF 
and IL-10. Both TLR9-stimulated and the synergistic BCR and TLR9-induced IL-6 production 
was significantly inhibited by XmAb5871 (Fig. 4). The Fc-KO antibody XENP6187 had no 
effect on TLR9 induced IL-6, but inhibited the dual signal-stimulated IL-6; however, IL-6 
production by the XmAb5871-treated dual-stimulated cells was significantly lower. IL-10 and 
TNF secretion induced by the dual anti-Ig and CpG ODN signals was significantly inhibited by 
XmAb5871 and XENP6187 as well. However, the effect of XmAb5871 was more pronounced in 
all cases. These data indicate that efficient FcγRIIb – CD19 coligation significantly diminished 
TLR9 and BCR-TLR9 dual signal-induced inflammatory cytokine secretion by human B cells; 
however, BCR and CD19 coengagement in the absence of FcγRIIb binding might also be 
inhibitory. 
Plasma cell differentiation is significantly reduced by XmAb5871. 
We next tested the IgG-producing cells in stimulated B cell cultures by ELISPOT assay. CpG 
ODN and CpG ODN plus anti-Ig in the presence of cytokines IL-2 and IL-10 both stimulated 
differentiation of B cells into IgG-producing plasma cells; under the conditions used the dual 
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signals were less efficient. XENP6187 did not significantly influence IgG production, while the 
XmAb5871-treated, CpG ODN-stimulated samples showed a significantly lower number of IgG-
synthesizing cells relative to the untreated ones (Fig. 5A).   
We compared the effect of XmAb5871 and XENP6187 in another B cell activation system. R848 
is a synthetic molecule that activates immune cells via the TLR7/TLR8 MyD88-dependent 
signaling pathway.35 R848 in the presence of IL-2 induces differentiation of IgG antibody-
forming cells (AFC). XmAb5871 statistically significantly inhibited (p<0.05) the differentiation 
of AFC as compared to XENP6187-treated samples (Fig.5B). 
 
XmAb5871 diminished the frequency of citrulline-containing peptide-specific antibody-
forming cells (AFC) triggered by TLR7/TLR8 agonist R848 in in vitro cultures of RA B 
cells. 
Approximately 70% of RA patients produce autoantibodies against citrullinated self-proteins, 
furthermore, anti-citrullinated protein/peptide-specific antibodies (ACPA) play a central role in 
the pathogenesis of the disease and are presently the most specific and sensitive marker for RA. 
26-28 We and others have previously shown that in vitro-activated B cells from ACPA-positive 
RA patients produce citrullinated peptide-specific IgG.36, 37 To see if XmAb5871 has an effect on 
citrulline peptide-specific antibody production, purified B cells from selected RA patients were 
cultured in the presence of IL-2 and R848 to stimulate memory B cells. The number of antibody-
producing cells was estimated on citrulline-containing filaggrin-peptide coated plates. 
XmAb5871 significantly diminished the number of peptide-specific spots, indicating that 
FcγRIIb-dependent inhibition of autoreactive B cells may indeed block autoantibody production 
(Fig. 5C).  
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Discussion 
B cells have a crucial role in adaptive immunity and play an important part in the pathogenesis of 
certain autoimmune diseases such as RA and SLE. Autoreactive B cells produce autoantibodies 
against self-peptides; furthermore, they have antibody-independent regulatory functions, 
especially in autoimmune diseases. For example, they play a role in activating pathogenic T 
cells,38 produce pro-inflammatory cytokines,39 and form ectopic lymphoid organs, such as 
germinal centers in the synovium of RA patients.40 B cells are central players in maintaining 
autoimmune inflammation; thus, targeting of B cell-specific surface molecules and blocking of B 
cell activation and survival are important tools to develop new and efficient therapies.41 
Rituximab, a chimeric monoclonal antibody specific for CD20, is the first selective B cell 
therapy for RA.42, 43 Rituximab therapy, however, has two drawbacks: 1) it has no effect on 
antibody-forming plasma cells, because plasma cells are negative for CD20; and 2) this therapy 
results in the depletion of peripheral B cells, which leads to a temporary immunosuppressed 
stage of the patients, leaving them vulnerable to infections.44, 45 Therefore, therapies based on 
targeting BCR signaling and leading to specific inhibition of B cell activation, without B cell 
depletion, may be advantageous.  
The Fc engineered anti-CD19 XmAb5871 was developed to bind to FcγRIIb with ~ 400 higher 
affinity compared to its native IgG1 counterpart.18-20 XmAb5871 has the capacity to block BCR 
signaling, to suppress humoral immunity, and to reduce serum IgM, IgG, and IgE levels in SCID 
mice engrafted with SLE, RA, or healthy human PBMC without depleting B cells.18-20 The 
mouse surrogate of XmAb5871 reduces BCR-induced calcium mobilization and cell activation 
in FcγRIIb transgenic mice.19 Furthermore, XmAb5871 stimulates the known FcγRIIb-mediated 
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inhibitory signaling pathway in B cells of SLE patients, suppressing calcium flux and B cell 
proliferation. However, the effect of XmAb5871 on TLR9 mediated signals, which are suggested 
to contribute to the development of autoimmunity, was not previously tested. 
Receptors of the adaptive and the innate immune system interact in regulating the immune 
response. Pathogen-associated molecular pattern receptors (PAMP) such as TLR9 may activate 
B cells independent of antigen; moreover, TLR9 acts synergistically with BCR, enhancing 
proliferation, cytokine and antibody production (unpublished results), thus promoting 
uncontrolled B cell activation that ultimately results in the development of autoimmunity. 
Indeed, signaling through the TLR pathway has been implicated in the pathogenesis of 
autoimmune diseases including RA and SLE.31 Therefore it is crucial to examine if XmAb5871 
influences TLR9-mediated signals in B cells. Our goal here was to study the effect of 
XmAb5871 on B cell functions mediated by the synergistic action of BCR and TLR9.  
We first confirmed that XmAb5871, but not the IgG1 control Fc-KO antibody, XENP6187, 
induced phosphorylation of Y292 in FcγRIIb, a prerequisite for inhibition. We also detected 
reduced ERK phosphorylation and a more significant decrease of AKT phosphorylation in all 
samples treated with XmAb5871. This could be a result of the decreased level of PIP3 in the cell 
membrane, evoked by FcγRIIb-recruited SHIP1. CD19, when phosphorylated by Lyn after 
coligation with BCR, recruits PI3K and enhances PI3K activity, elevating PIP3 level in the cell 
membrane, which can explain the increased AKT phosphorylation in the XENP6187-treated 
samples. This activatory effect of CD19 crosslinking was more than negated by the amplified 
FcγRIIb-dependent signal in XmAb5871-treated B cells.  
Intracellular calcium mobilization is induced by the crosslinking of BCR or CD19. XENP6187 
control antibody, lacking binding to Fcγ receptors, enhanced [Ca2+]i in BCR and CD19 
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cocrosslinked B cells, while in agreement with previous data, XmAb5871 inhibited the BCR 
stimulated response, indicating that high-affinity binding of this antibody to FcγRIIb blocks the 
calcium signal mediated by BCR-CD19 interaction. 
To study the functional consequences of XmAb5871-mediated impaired signal transduction by 
TLR9 and BCR, we assessed this antibody's effects on cell proliferation, cytokine production and 
plasma-cell differentiation. XmAb5871 inhibited all three functions albeit by different degrees.  
Surprisingly, anti-CD19 antibody XENP6187 still inhibited B cell functions, although less 
efficiently than XmAb5871. These results are in agreement with earlier findings that crosslinking 
CD19 may have an inhibitory effect on later events of B cell activation, depending on the context 
of stimulation.16, 46-48 It was suggested that anti-CD19 mAb exerts its inhibitory effect on anti-
IgM induced B cell proliferation in late G0 or G1, after the initial signaling events.48 This might 
explain the apparent inconsistency between the lack of inhibition of early signaling events and 
the partial inhibition of late events of B cell activation by XENP6187. 
Furthermore, CD19 can physically interact with BTK following BCR ligation, which is 
important for the prolonged phosphorylation of the kinase.49 A recent paper claims that TLR9 
and BCR cosignaling also depend on BTK, which is essential for the colocalization of BCR and 
TLR9.32 Taking all of these results together, we suggest that in the case of BCR-CD19 
crosslinking by anti-IgG and XENP6187, BTK is exhausted by CD19 and is not available for 
BCR-TLR9-induced synergistic signaling. Alternatively, XENP6187 antibody, by crosslinking 
CD19, might induce phosphorylation via the Lyn kinase of some other negatively regulating 
molecule on B cells, such as CD22.50 
It is notable that the Fc-enhanced anti-CD19 antibody significantly inhibited the inflammatory 
cytokine IL-6 and reduced TNF secretion from B cells stimulated via BCR and TLR9. This 
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might have functional significance in RA therapy because RA patients have increased levels of 
IL-6 and TNF in their circulation that promotes inflammation. XmAb5871 also reduced the 
number of IgG-producing cells in TLR9-stimulated B cell cultures of healthy individuals. The 
combined stimuli of IL-2 and R848, a synthetic ligand for TLR7/TLR8, selectively stimulate 
human memory B cells leading to differentiation of IgG-secreting AFC. XmAb5871 treatment 
significantly reduced the number of AFC in R848-stimulated healthy B cell culture as compared 
to XENP6187-treated cells. Thus, the simultaneous ligation of CD19 and FcγRIIb inhibits TLR9- 
and TLR7/TLR8-mediated B cell activation and differentiation as well.  
Approximately 70% of RA patients produce antibody specific for citrullinated proteins/peptides 
(ACPA); furthermore, in vitro production of citrulline peptide-specific antibodies by RA B cells 
was shown previously. When XmAb587-treated, R848 prestimulated B cells of RA patients were 
tested, we detected a significant reduction in the number of antibody-forming cells specific for 
citrullinated filaggrin peptide, a characteristic epitope recognized by sera of RA patients, 
indicating that XmAb5871 is able to suppress autoantibody production in RA B cells. 
 
Taking together, we show here that XmAb5871 inhibits BCR-, TRL9- and dual signal-induced B 
cell activation, proliferation and inflammatory cytokine and IgG production. Moreover, 
XmAb5871 inhibits the differentiation of citrullinated filaggrin peptide-specific antibody-
producing cells from RA patients, suggesting that this antibody has potential as an alternative B 
cell suppressive therapy in RA. 
 
Materials and methods 
Ethics statement and patients 
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Blood samples were taken from healthy blood donors and from RA patients after written consent 
with ethical permission of the Scientific Research Ethics Committee of the Medical Scientific 
Board of the Hungarian Ministry of Human Resources (ETT TUKEB 5257-0/2010-1018EKU 
376/PI/010). The diagnosis of the disease was established on the basis of the revised 
ACR/EULAR classification criteria. 51 Purified B cells from six RA patients (male/female: 1/5, 
age: 38-66 years, ACPA titer determined with anti-CCP2 test: 135-3200) were tested. Additional 
blood samples were taken from healthy blood donors, and tonsils were obtained from patients 
undergoing tonsillectomy after written consent with ethical permission as above (ETT TUKEB 
84-402/2008-1018EKU 1010/PI2008). The Scientific Research Ethics Committee of the Ministry 
specifically approved all studies. 
Reagents and antibodies 
Affinity-purified F(ab')2 fragment of goat anti-human IgG + IgM (H+L) (109-006-1270) was 
purchased from Jackson Immunoresearch Laboratories, phosphorothioated unmethylated CpG 
oligodeoxynucleotide (ODN-2006) (5’-tcgtcgttttgtcgttttgtcgt’-3’) was purchased from Sigma-
Aldrich, and IL-2 (11340025) and IL-10 (11340105) were obtained from ImmunoTools. Anti-
human CD19 with the Fc-KO mutations, XENP6187 and anti-human CD19 with FcγRIIb-
enhanced IgG1 Fc (XmAb5871) were produced by Xencor. CD19-APC (21270196), CD27-APC 
(21270276) and CD38-FITC (21270383) were purchased from BD Biosciences. Phospho-AKT 
(Ser473, 4060) and phospho-ERK (Thr202/Tyr204, 4370)-specific antibodies were purchased 
from Cell Signaling Technology, and phospho-FcγRIIb (Tyr292, 2308-1) was from Epitomics. 
Rabbit anti-SHP2 (sc-30687) was from Santa Cruz Biotechnology, secondary goat anti-rabbit 
IgG-HRP (7074)-conjugated antibodies were from Cell Signaling Technology, and Luminata 
Forte HRP substrate (WBLUF0500) was purchased from Millipore. Biotinylated and 
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citrullinated epitope peptide of filaggrin 306SHQESTXGXSXGRSGRSGS326 (X stands for 
citrulline) was a generous gift from Dr. Anna Magyar (Research Group of Peptide Chemistry, 
Hungarian Academy of Sciences, Eötvös Loránd University, Budapest, Hungary). 
Isolation and activation of B cells 
PBMCs were isolated by density gradient centrifugation on Ficoll-Paque PLUS (GE Healthcare, 
17-1440-03) and B lymphocytes were purified by negative selection using Magnetic Bead-
Activated Cell Sorting (MACS, 130-091-151) according to the manufacturer's protocol (Miltenyi 
Biotec). B cell purity was assessed by flow cytometry using anti-human CD19-APC antibody. B 
cells with purity over 95% were used in most experiments, while B cells with purity over 99% 
were used in experiments investigating cytokine production. 
Tonsils were obtained from patients undergoing tonsillectomy. Mononuclear cells were isolated 
by Ficoll-Paque PLUS density gradient centrifugation and T cells were depleted after rosette 
formation with sheep red blood cells followed by a second density gradient centrifugation. For 
western blot analysis, resting tonsil B cells were isolated by Percoll gradient centrifugation. 52 
The purity of the resultant B cell suspension was over 95%. Tonsil B cells were further purified 
by positive magnetic bead separation for the cytokine production experiments.  
To analyze synergistic activation, suboptimal doses of stimulants were used. B cells were 
activated by crosslinking the BCR with 2.5 μg/ml F(ab')2 fragment affinity-purified anti-human 
IgG + IgM in the presence or absence of 1 μg/ml CpG oligonucleotide (ODN). To test the effect 
of Fc-engineered antibodies on FcγRIIb, AKT and ERK phosphorylation, cells were pre-treated 
with XmAb5871 or  the Fc-KO XENP6187 for 30 min at 37oC (10 μg/ml). For functional assays, 
anti-human IgG + IgM, CpG ODN and respective anti-CD-19 antibodies were mixed before 
adding to the cells. Cell types, concentrations and times are indicated below the figures. 
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Western blot analysis 
2 x 106 resting tonsillar B cells were activated per sample. After 30 min pretreatment of cells 
with XmAb5871 or XENP6187, the cells were activated via BCR or TLR9 for 30 minutes, then 
pelleted and lysed in 50 μl lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, and 1% Triton X-100, supplemented with protease and phosphatase inhibitors (2.5 
mM Na3VO4, 1 mM PMSF, 1.5 mM aprotinin, 10 mM leupeptin). Cell lysates were mixed at 4:1 
with 5 times concentrated reducing sample buffer. Samples were subjected to SDS-PAGE under 
reducing condition, and proteins were transferred electrophoretically to nitrocellulose 
membranes (Bio-Rad Laboratories, 162-0115). Membranes were blocked with 5% bovine serum 
albumin (BSA, Sigma-Aldrich, A7030) in TBS with 0.1% Tween 20 for 1 h, then incubated 
overnight with primary antibodies specific for the phosphorylated forms of various proteins. 
After several washings with Tris-washing buffer (TWB-Tween), horseradish peroxidase (HRP)-
conjugated species-specific antibodies were added, and reactive protein bands were visualized 
using Luminata Forte HRP substrate. SHP2 was used as loading control. 
Calcium mobilization 
Intracellular free calcium concentration ([Ca 2+]i) was measured by flow cytometry using Fluo-4 
(Invitrogen)-stained purified blood B cells. Cells were resuspended at 5×106 cells/ml in calcium 
assay buffer and loaded with Fluo-4 dye for 30 min at room temperature. After incubation with 
10 μg/ml anti-CD19 antibodies, cells were stimulated by addition of 10 μg/ml of anti-Ig. 
Calcium flux kinetics were recorded using a FACSCalibur flow cytometer (Becton-Dickinson) 
and data were analyzed using FlowJo software (TreeStar). 
Proliferation assay 
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106 – 107 purified peripheral blood B cells were incubated with 5 μM carboxyfluorescein 
diacetate succinimidyl ester (CFSE, Biolegend, 422701) in 5% FCS containing PBS for 10 min 
at 37°C. After repeated washings with ice-cold RPMI 1640 medium, cells were transferred into 
96-well plates (4 x 105 cells/well) and cultured for 5 days at 37°C in complete medium 
containing different stimuli with or without the respective anti-CD19 antibody. Cell cultures 
were harvested and CFSE staining was analyzed by flow cytometry. Dead cells were stained 
with propidium iodide (PI, Sigma-Aldrich, P-4170) and gated out. The results were evaluated by 
FlowJo software. 
Cytokine production 
Secretion of IL-6, IL-10 and TNF cytokines was measured in the supernatants of purified blood 
B cells stimulated under various conditions. 2 x 105 cells were stimulated per sample. The 
supernatants were collected after 48 h and stored at -70°C until assayed by Flow Cytomix bead 
array (Bender MedSystem, BMS8213FF, BMS8215FF and BMS8223FF) according to the 
manufacturer’s instructions. 
Total IgG ELISPOT assay 
105 purified blood B cells were added per well of a 96-well round-bottom plate in 200 μl culture 
media containing IL-2, IL-10 (50 ng/ml), and different combinations of activators as indicated in 
the figure. Alternatively, B cells were stimulated in the presence of 10 ng/ml rhIL-2 and 1 μg/ml 
R848 (Sigma-Aldrich, SML0196) a polyclonal activator. Cells were cultured for three days at 
37°C and in 5% CO2 containing atmosphere. The frequencies of IgG secreting cells were 
evaluated by ELISPOT assay.53 Briefly, 96-well MultiScreenHTS-IP filter plates (Millipore, 
MAHAN4550) were pre-treated with 70% ethanol and washed 3 times in sterile PBS before 
coating overnight at 4°C with 5 μg/ml mouse anti-human IgG (BD Biosciences, 555784). Plates 
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were washed in sterile PBS and blocked with PBS containing 3% BSA. A serial dilution of 
cultured B cells was added and incubated at 37°C. After 20 h incubation, cells were aspirated and 
plates were washed with PBS containing 0.1% Tween 20. Horse radish peroxidase (HRP) 
conjugated mouse anti-human IgG (BD Biosciences, 555788) detection antibody (1:1000) was 
added, and after two hours of incubation plates were subjected to several washes, then spots were 
developed with  TMB substrate (MabTech, 3651-10), and counted using the CTL Immunospot 
Reader (Cellular Technologies Ltd.). 
Peptide-specific ELISPOT assay 
The assay was carried out as previously described.37 Briefly, purified B cells from RA patient 
blood were isolated using MACS. 106 cells/ml were cultured in RPMI 1640 containing 10% FCS 
in the presence of 10 ng/ml rhIL-2 and 1 μg/ml R848 (Sigma-Aldrich, SML0196) polyclonal 
activator with or without XmAb5871.54 Cells were harvested on the third day, washed and 
counted, and then were transferred into the wells of ELISPOT plates precoated with neutravidin 
and the biotinylated citrulline-containing 19mer filaggrin peptide 
(SHQESTXGXSXGRSGRSGS, X stands for citrulline).37 The spots were developed after 20 h. 
Statistical analysis 
Data are reported as means ± standard deviation and were analyzed using GraphPad Prism 4. 
Paired Student’s t test was used to compare groups. P values of <0.05 were considered 
statistically significant. 
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Figure legends 
Figure 1. XmAb5871 suppresses BCR and TLR9-induced signals through phosphorylation 
of FcγRIIb 
Purified human resting tonsillar B cells were pre-treated with media or 10 μg/ml XENP6187 or 
XmAb5871, respectively, for 1 h before activation with anti-Ig (2.5 μg/ml) or CpG (1 μg/ml) for 
30 min. Cell lysates were western-blotted to assess phosphorylation and activation of FcγRIIb, 
AKT and ERK. One representative experiment from three independent ones is shown. 
Figure 2. XmAb5871 inhibits while XENP6187 enhances calcium mobilization when CD19 
is coligated with BCR 
Fluo-4 loaded B cells were treated with either XmAb5871 or the Fc-KO XENP6187 antibodies 
and then stimulated with 10 μg/ml anti-Ig. Calcium flux kinetics was recorded using 
FACSCalibur flow cytometer and data were analyzed by FlowJo software. Data represent the 
average of two independent experiments. 
Figure 3. Effect of XmAb5871 on BCR and TLR9-induced proliferation. 
(A) Representative flow cytometry histograms of CFSE-labeled human blood B cells stimulated 
with combinations of 2.5 μg/ml anti-Ig and 1 μg/ml CpG in the presence of 10 μg/ml XENP6187 
or XmAb5871 for 5 days. Peaks shifted to the left represent cell populations undergoing 
increasing numbers of cell division. Total percentages of dividing cells are shown. (B) 
Percentages of dividing cells (mean ± SD) in three independent experiments. B cells were 
stimulated with anti-Ig, CpG ODN or with the combination of the two in the presence or absence 
of XENP6187 or XmAb5871. XmAb5871 significantly reduced proliferation of both CpG and 
anti-Ig plus CpG stimulated cells, *: p <0.05. 
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Figure 4. XmAb5871 inhibits BCR and TLR9-induced IL-6, IL-10 and TNF production by 
B cells. 
B cells cultured in 96-well plates were activated by 2.5 μg/ml anti-Ig or 1 μg/ml CpG ODN in 
the presence of XmAb5871 or the control antibody XENP6187. IL-6, IL-10 and TNF secreted 
from the culture supernatants were measured after 48 hr using the Flow Cytomix bead array. 
Data represent the mean ± SD of four independent experiments. XmAb5871 significantly 
inhibits IL-6 production induced by anti-Ig and CpG, as compared to XENP6187 treated cells. *: 
p <0.05. 
Figure 5. The effect of XmAb5871 on total and citrullinated peptide-specific IgG 
production as detected by ELISPOT assay 
(A) Purified human B cells were cultured with anti-Ig (2.5 μg/ml) or CpG (0.5 μg/ml) for 3 days 
in the presence of IL-2 (50ng/ml) and IL-10 (50 ng/ml), and XmAb5871 or XENP6187 (10 
μg/ml), respectively. The number of IgG-secreting cells was evaluated by ELISPOT assay on 
anti-IgG-coated nitrocellulose plates. Data represent the mean ± SD of seven independent 
experiments. *: p <0.05. 
B) B cells were stimulated by IL-2 (10 ng/ml) and R848 (1 μg/ml) for 3 days in the presence of 
XENP6187or XmAb5871 antibodies. The number of IgG-secreting cells was assessed as above. 
Data represent the mean ± SD of seven independent experiments. *: p <0.05. 
(C) Citrullinated filaggrin peptide-specific IgG-producing B cells were tested upon activation 
with IL-2 (10 ng/ml) and R848 (1 μg/ml) for 3 days with or without XmAb5871. The 
citrullinated filaggrin peptide-specific IgG secreting cells were detected on peptide-coated 
nitrocellulose plates. The results for B cells from six different ACPA-positive RA patients are 
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shown. XmAb5871 significantly inhibited the development of citrullin-containing filaggrin 
peptide-specific antibody-forming cells, *: p <0.05.  
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